Intra-aortic balloon pumping has recently been shown to be ineffective in treating cardiogenic shock due to myocardial infarction. Other, more potent percutaneous pumps have been developed, and their use is growing substantially, but they have not been studied in randomized trials. Two new reports provide provocative information about these devices.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Burkhoff, D. & Naidu, S. S. The science behind percutaneous hemodynamic support: a review and comparison of support strategies. Catheter. Cardiovasc. Interv. 80, 816–829 (2012).
Thiele, H. et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N. Engl. J Med. 367, 1287–1296 (2012).
Windecker, S. et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur. Heart J. 35, 2541–2619 (2014).
O'Gara, P. T. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation 127, e362–e425 (2013).
Ahmad, Y. et al. Intra-aortic balloon pump therapy for acute myocardial infarction: a meta-analysis. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2015.0569.
Khera, R. et al. Trends in the use of percutaneous ventricular assist devices: analysis of National Inpatient Sample data, 2007 through 2012. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2014.7856.
Seyfarth, M. et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J. Am. Coll. Cardiol. 52, 1584–1588 (2008).
Alexander, J. H. et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297, 1657–1666 (2007).
Thiele, H., Ohman, E. M., Desch, S., Eitel, I. & de Waha, S. Management of cardiogenic shock. Eur. Heart J. 36, 1223–1230 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.B. declares that he is an employee of HeartWare International, and a consultant to BackBeat Medical, CardiacImplants, DC Devices Inc., and Sensible Medical. He has received grant support from Abiomed, is on the Heart Failure Advisory Board of the Sorin Group, and is the founder of PVLoops LLC.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Burkhoff, D. Where next in cardiogenic shock owing to myocardial infarction?. Nat Rev Cardiol 12, 383–385 (2015). https://doi.org/10.1038/nrcardio.2015.81
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2015.81